RxDoctor Payments Data

Amanda Ball

Primary Care · Newbury Park, CANPI 1891419073

Payments from drug & device makers

$1,162in general payments, 2019–2025

Across 55 payments — averaging $21.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$264
  • Sumitomo Pharma America, Inc.$188
  • Shionogi Inc$188
  • Paratek Pharmaceuticals, Inc.$158
  • Melinta Therapeutics, LLC$106
  • Aimmune Therapeutics, Inc.$53
  • plus $204 from 8 others

What the payments were for

  • Food & beverage$1,160100%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,162 in reported general payments places this provider in the 75th percentile of 706 primary care providers in California.

See all primary care providers in California

Medicare billing

Part B allowed, 2024
$55,103
Medicare patients
199
Services billed
642

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf26$155,807
BiktarvyBictegrav/Emtricit/Tenofov Ala25$98,245
CompleraEmtricita/Rilpivirine/Tenof Df11$51,363
OzempicSemaglutide22$22,159
BriviactBrivaracetam12$16,875
EliquisApixaban18$16,569
LinzessLinaclotide17$10,488
CreonLipase/Protease/Amylase11$8,685
SynthroidLevothyroxine Sodium42$4,275
Dexlansoprazole DrDexlansoprazole17$3,177
PaxlovidNirmatrelvir/Ritonavir11$2,859
ValacyclovirValacyclovir Hcl51$2,010
Gabapentin87$1,491
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen51$1,363
Wixela InhubFluticasone Propion/Salmeterol12$1,300

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$264$98,24525 claims
AbbVieLinzess, Creon, Synthroid$18$23,44870 claims
PfizerEliquis, Paxlovid$22$19,42829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 706 primary care providers in California.

Other primary care in Newbury Park

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →